Active substance
Tazarotene
- SFDA 4
- US FDA 15
- Health Canada 1
- US price lines 8
- Safety 3
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| EVITAR 0.1% gel | 0.1 % | Gel · Topical | 1 Tube | SAR 54.50 | Generic · Prescription | DEEF PHARMACEUTICAL INDUSTRIES | Valid |
| EVITAR 0.1% gel | 0.1 % | Gel · Topical | 1 Tube | SAR 95.00 | Generic · Prescription | DEEF PHARMACEUTICAL INDUSTRIES | Valid |
| EVITAR 0.1% gel | 0.1 % | Gel · Topical | 1 Tube | SAR 139.95 | Generic · Prescription | DEEF PHARMACEUTICAL INDUSTRIES | Valid |
| EVITAR 0.1% gel | 0.1 % | Gel · Topical | 1 Tube | SAR 180.00 | Generic · Prescription | DEEF PHARMACEUTICAL INDUSTRIES | Valid |
Indications — CHI Daman Drug Formulary
PSORIASIS; SYSTEMIC LUPUS ERYTHEMATOSUS
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| TAZORAC | 0.05%; 0.1% | gel · topical | CHARTWELL RX | Prescription | 13 Jun 1997 |
| TAZORAC | 0.05%; 0.1% | cream · topical | CHARTWELL RX | Prescription | 29 Sep 2000 |
| AVAGE | 0.1% | cream · topical | CHARTWELL RX | Prescription | 29 Sep 2000 |
| FABIOR | 0.1% | aerosol, foam · topical | MAYNE PHARMA | Prescription | 11 May 2012 |
| TAZAROTENE | 0.1% | cream · topical | SUN PHARMA CANADA | Prescription | 3 Apr 2017 |
| TAZAROTENE | 0.1%; 0.05% | cream · topical | COSETTE PHARMS NC | Prescription | 22 Dec 2017 |
| ARAZLO | 0.045% | lotion · topical | BAUSCH | Prescription | 18 Dec 2019 |
| TAZAROTENE | 0.1% | gel · topical | COSETTE PHARMS NC | Prescription | 13 Sep 2022 |
| TAZAROTENE | 0.05% | gel · topical | COSETTE PHARMS NC | Prescription | 13 Sep 2022 |
| TAZAROTENE | 0.05%; 0.1% | gel · topical | SOLARIS PHARMA CORP | Prescription | 20 Mar 2023 |
| TAZAROTENE | 0.05%; 0.1% | gel · topical | PADAGIS ISRAEL | Prescription | 25 Apr 2023 |
| TAZAROTENE | 0.05% | cream · topical | PADAGIS ISRAEL | Prescription | 15 Jul 2024 |
| TAZAROTENE | 0.05% | cream · topical | SOLARIS PHARMA CORP | Prescription | 24 Nov 2025 |
| TAZAROTENE | 0.1% | cream · topical | FOUGERA PHARMS INC | Discontinued | 28 Jan 2019 |
| TAZAROTENE | 0.045% | lotion · topical | PADAGIS ISRAEL | Discontinued | 29 Jul 2025 |
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| ARAZLO | 02517868 | 0.045 % / W/W | LOTION · TOPICAL | BAUSCH HEALTH, CANADA INC. |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | FABIOR 0.1% FOAM | $12.32276 | per GM | 17 Jun 2026 |
| US NADAC | TAZAROTENE 0.05% CREAM | $6.88896 | per GM | 23 Sep 2026 |
| US NADAC | TAZAROTENE 0.05% CREAM | $8.06818 | per GM | 23 Sep 2026 |
| US NADAC | TAZAROTENE 0.05% GEL | $5.31381 | per GM | 23 Sep 2026 |
| US NADAC | TAZAROTENE 0.1% CREAM | $1.92446 | per GM | 23 Sep 2026 |
| US NADAC | TAZAROTENE 0.1% CREAM | $1.84922 | per GM | 23 Sep 2026 |
| US NADAC | TAZAROTENE 0.1% GEL | $6.50389 | per GM | 23 Sep 2026 |
| US NADAC | TAZAROTENE 0.1% GEL | $5.7146 | per GM | 23 Sep 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Safety signals and safety-related labeling changes
- US FDA 16 Apr 2018 TAZORAC — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 21 Jul 2017 AVAGE — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 21 Jul 2017 TAZORAC — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide
Combinations containing Tazarotene
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.